Grant Number:	1R01CA132946-01 Interpret this number
Primary Investigator:	Lamba, Jatinder
Organization:	St. Jude Children'S Research Hospital
Project Title:	Pharmacogenetics of Ara-C Metabolic Pathway
Fiscal Year:	2008

DESCRIPTION (provided by applicant): The nucleoside analog cytarabine (ara-C) has been the mainstay of acute myeloid leukemia (AML) chemotherapy for more than 40 years and is one of the most important drugs used to induce remission in patients with AML. A number of studies suggest that the intracellular concentration of its active metabolite, ara-CTP, varies widely among patients and in turn is associated with variability in clinical response. The objective of the current proposal is to determine the molecular basis of this variation in intracellular ara-CTP levels by identifying and evaluating the pharmacogenomic effect of genetic polymorphisms in key genes in the ara-C metabolic pathway, with the long-term goal of explaining the variability observed in treatment response and toxicity profile among AML patients receiving ara-C chemotherapy. The hypothesis of this research is that genetic polymorphisms in key genes in the ara-C metabolic pathway -specifically: deoxycytidine kinase (DCK, a rate limiting activating enzyme); 5'nucleotidase (NT5C2), deoxycytidine deaminase (CDA), and deoxycytidylate deaminase (DCTD) (3 main inactivating enzymes); human equilibrative nucleoside transporter (hENT1/ SLC29A1, ara-C uptake transporter); and ribonucleotide reductase (enzyme regulating intracellular dCTP pools, and consisting of RRM1 and RRM2 subunits) -form the molecular basis of the inter-patient variability observed in intracellular ara-CTP concentration and sensitivity to ara-C. This hypothesis is based on the observations that the above mentioned candidate genes have been shown by various in vitro and in vivo studies to be associated with the clinical response and/or sensitivity to ara-C and demonstrate a wide inter- patient variability in their expression. The specific aims of the proposed research are: 1) To identify and functionally characterize the coding genetic polymorphisms in key ara-C metabolic pathway genes in lymphoblast samples with European (CEPH) or African (YRI) ancestry; 2) To identify and characterize regulatory cis-genetic polymorphisms associated with mRNA expression of the candidate genes; and 3) To determine the association of functionally significant genetic polymorphisms in the candidate genes with clinical phenotypes such as candidate gene expression and ara-C sensitivity in diagnostic blasts, and intracellular ara- CTP levels and the extent of DNA synthesis inhibition in post ara-C treatment leukemic blasts from pediatric AML patients enrolled in the St. Jude AML2002 protocol. The use of CEPH and YRI samples will allow us to use HAPMAP genotype data and to study any ethnic differences in genotype frequencies and in candidate gene expression. The results from this study would also be applicable to other nucleoside analogs such as gemcitabine, decitabine, clofarabine, etc. that are metabolized by the same pathway. Understanding genetic variation in the key candidate genes involved in the metabolism of ara-C will provide us an opportunity to identify patients at increased risk of adverse reactions or decreased likelihood of response, based upon their genetic profile, which in future could help in dose optimization to reduce drug toxicity without compromising on efficacy. Relevance Statement: Acute myeloid leukemia (AML) is the second most common childhood leukemia and has the worst outcome of all major childhood cancers. Ara-C is the main drug used in AML chemotherapy but the cellular levels of its active form, ara-CTP, vary widely among patients and in turn are associated with variability in clinical response to ara-C treatment. The proposed research seeks to explain this variability by studying the inherited genetic variation in key genes involved in ara-C metabolism and may, in future, help to optimize ara-C dosing based on patient genetics.




Bootstrap Evaluation of Association Matrices (BEAM) for Integrating Multiple Omics Profiles with Multiple Outcomes.
Authors: Seffernick A.E. , Cao X. , Cheng C. , Yang W. , Autry R.J. , Yang J.J. , Pui C.H. , Teachey D.T. , Lamba J.K. , Mullighan C.G. , et al. .
Source: Biorxiv : The Preprint Server For Biology, 2024-08-03 00:00:00.0; , .
EPub date: 2024-08-03 00:00:00.0.
PMID: 39131398
Related Citations

Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials.
Authors: H Elsayed A. , Cao X. , Marrero R.J. , Nguyen N.H.K. , Wu H. , Ni Y. , Ribeiro R.C. , Tobias H. , Valk P.J. , Béliveau F. , et al. .
Source: Npj Precision Oncology, 2024-08-01 00:00:00.0; 8(1), p. 168.
EPub date: 2024-08-01 00:00:00.0.
PMID: 39090192
Related Citations

Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia.
Authors: Marrero R.J. , Wu H. , Cao X. , Parcha P.K. , Elsayed A.H. , Inaba H. , Kuo D.J. , Degar B.A. , Heym K. , Taub J.W. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2024-07-30 00:00:00.0; , .
EPub date: 2024-07-30 00:00:00.0.
PMID: 39078289
Related Citations

Current Landscape of Genome-Wide Association Studies in Acute Myeloid Leukemia: A Review.
Authors: Marrero R.J. , Lamba J.K. .
Source: Cancers, 2023-07-12 00:00:00.0; 15(14), .
EPub date: 2023-07-12 00:00:00.0.
PMID: 37509244
Related Citations

Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.
Authors: Nguyen N.H.K. , Rafiee R. , Tagmount A. , Sobh A. , Loguinov A. , de Jesus Sosa A.K. , Elsayed A.H. , Gbadamosi M. , Seligson N. , Cogle C.R. , et al. .
Source: Blood Advances, 2023-05-09 00:00:00.0; 7(9), p. 1769-1783.
PMID: 36111891
Related Citations

Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study.
Authors: Larkin T. , Kashif R. , Elsayed A.H. , Greer B. , Mangrola K. , Raffiee R. , Nguyen N. , Shastri V. , Horn B. , Lamba J.K. .
Source: Jco Precision Oncology, 2023 Mar; 7, p. e2200580.
PMID: 36952646
Related Citations

SAMHD1 Single Nucleotide Polymorphisms Impact Outcome in Children with Newly Diagnosed Acute Myeloid Leukemia.
Authors: Marrero R.J. , Cao X. , Wu H. , Elsayed A.H. , Klco J.M. , Ribeiro R.C. , Rubnitz J.E. , Ma X. , Meshinchi S. , Aplenc R. , et al. .
Source: Blood Advances, 2023-01-23 00:00:00.0; , .
EPub date: 2023-01-23 00:00:00.0.
PMID: 36689724
Related Citations

Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
Authors: Elsayed A.H. , Cao X. , Mitra A.K. , Wu H. , Raimondi S. , Cogle C. , Al-Mansour Z. , Ribeiro R.C. , Gamis A. , Kolb E.A. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2022-03-01 00:00:00.0; 40(7), p. 772-783.
EPub date: 2022-01-06 00:00:00.0.
PMID: 34990262
Related Citations

Proteomics: a new era in pediatric acute myeloid leukemia research.
Authors: Lamba J.K. , Pounds S. .
Source: Haematologica, 2022-01-13 00:00:00.0; , .
EPub date: 2022-01-13 00:00:00.0.
PMID: 35021610
Related Citations

Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators.
Authors: Fornerod M. , Ma J. , Noort S. , Liu Y. , Walsh M.P. , Shi L. , Nance S. , Liu Y. , Wang Y. , Song G. , et al. .
Source: Blood Cancer Discovery, 2021 Nov; 2(6), p. 586-599.
EPub date: 2021-09-09 00:00:00.0.
PMID: 34778799
Related Citations

Global Proteomic Profiling of Pediatric AML: A Pilot Study.
Authors: Nguyen N.H.K. , Wu H. , Tan H. , Peng J. , Rubnitz J.E. , Cao X. , Pounds S. , Lamba J.K. .
Source: Cancers, 2021-06-24 00:00:00.0; 13(13), .
EPub date: 2021-06-24 00:00:00.0.
PMID: 34202615
Related Citations

DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML.
Authors: Lamba J.K. , Cao X. , Raimondi S. , Downing J. , Ribeiro R. , Gruber T.A. , Rubnitz J. , Pounds S. .
Source: Cancers, 2020-10-17 00:00:00.0; 12(10), .
EPub date: 2020-10-17 00:00:00.0.
PMID: 33080932
Related Citations

Correction: A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
Authors: Elsayed A.H. , Rafiee R. , Cao X. , Raimondi S. , Downing J.R. , Ribeiro R. , Fan Y. , Gruber T.A. , Baker S. , Klco J. , et al. .
Source: Leukemia, 2020 Oct; 34(10), p. 2821.
PMID: 32300185
Related Citations

DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Authors: Buelow D.R. , Anderson J.T. , Pounds S.B. , Shi L. , Lamba J.K. , Hu S. , Gibson A.A. , Goodwin E.A. , Sparreboom A. , Baker S.D. .
Source: Clinical And Translational Science, 2020-09-09 00:00:00.0; , .
EPub date: 2020-09-09 00:00:00.0.
PMID: 32905646
Related Citations

A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
Authors: Elsayed A.H. , Rafiee R. , Cao X. , Raimondi S. , Downing J.R. , Ribeiro R. , Fan Y. , Gruber T.A. , Baker S. , Klco J. , et al. .
Source: Leukemia, 2020 Mar; 34(3), p. 735-745.
EPub date: 2019-10-23 00:00:00.0.
PMID: 31645648
Related Citations

CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.
Authors: Papageorgiou I. , Loken M.R. , Brodersen L.E. , Gbadamosi M. , Uy G.L. , Meshinchi S. , Lamba J.K. .
Source: Leukemia & Lymphoma, 2019 09; 60(9), p. 2287-2290.
EPub date: 2019-02-05 00:00:00.0.
PMID: 30721105
Related Citations

A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Authors: Drusbosky L.M. , Singh N.K. , Hawkins K.E. , Salan C. , Turcotte M. , Wise E.A. , Meacham A. , Vijay V. , Anderson G.G. , Kim C.C. , et al. .
Source: Blood Advances, 2019-06-25 00:00:00.0; 3(12), p. 1837-1847.
PMID: 31208955
Related Citations

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
Authors: Rafiee R. , Chauhan L. , Alonzo T.A. , Wang Y.C. , Elmasry A. , Loken M.R. , Pollard J. , Aplenc R. , Raimondi S. , Hirsch B.A. , et al. .
Source: Blood Cancer Journal, 2019-05-21 00:00:00.0; 9(6), p. 51.
EPub date: 2019-05-21 00:00:00.0.
PMID: 31113932
Related Citations

MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia.
Authors: Bhise N.S. , Elsayed A.H. , Cao X. , Pounds S. , Lamba J.K. .
Source: Genes, 2019-04-24 00:00:00.0; 10(4), .
EPub date: 2019-04-24 00:00:00.0.
PMID: 31022985
Related Citations

Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
Authors: Gbadamosi M. , Meshinchi S. , Lamba J.K. .
Source: Future Oncology (london, England), 2018 Dec; 14(30), p. 3199-3213.
EPub date: 2018-07-24 00:00:00.0.
PMID: 30039981
Related Citations

leukemic cell sensitivity to cytarabine in pediatric AML.
Authors: Bargal S.A. , Rafiee R. , Crews K.R. , Wu H. , Cao X. , Rubnitz J.E. , Ribeiro R.C. , Downing J.R. , Pounds S.B. , Lamba J.K. .
Source: Oncotarget, 2018-10-09 00:00:00.0; 9(79), p. 34859-34875.
EPub date: 2018-10-09 00:00:00.0.
PMID: 30405880
Related Citations

Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.
Authors: Elsayed A.H. , Cao X. , Crews K.R. , Gandhi V. , Plunkett W. , Rubnitz J.E. , Ribeiro R.C. , Pounds S.B. , Lamba J.K. .
Source: Pharmacogenomics, 2018-09-01 00:00:00.0; 19(14), p. 1101-1110.
EPub date: 2018-08-08 00:00:00.0.
PMID: 30088438
Related Citations

Correction: Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.
Authors: Lamba J.K. , Cao X. , Raimondi S.C. , Rafiee R. , Downing J.R. , Shi L. , Gruber T. , Ribeiro R.C. , Rubnitz J.E. , Pounds S.B. .
Source: Oncotarget, 2018-07-13 00:00:00.0; 9(54), p. 30473.
EPub date: 2018-07-13 00:00:00.0.
PMID: 30101002
Related Citations

Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.
Authors: Lamba J.K. , Cao X. , Raimondi S.C. , Rafiee R. , Downing J.R. , Lei S. , Gruber T. , Ribeiro R.C. , Rubnitz J.E. , Pounds S.B. .
Source: Oncotarget, 2018-06-01 00:00:00.0; 9(42), p. 26711-26723.
EPub date: 2018-06-01 00:00:00.0.
PMID: 29928480
Related Citations

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia.
Authors: Stockard B. , Garrett T. , Guingab-Cagmat J. , Meshinchi S. , Lamba J. .
Source: Scientific Reports, 2018-04-03 00:00:00.0; 8(1), p. 5534.
EPub date: 2018-04-03 00:00:00.0.
PMID: 29615816
Related Citations

CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.
Authors: Lamba J.K. , Voigt A.P. , Chauhan L. , Shin M. , Aplenc R. , Eidenschink Brodersen L. , Gamis A.S. , Meshinchi S. , Loken M.R. .
Source: Leukemia & Lymphoma, 2018-01-10 00:00:00.0; , p. 1-4.
EPub date: 2018-01-10 00:00:00.0.
PMID: 29320902
Related Citations

Cc-promise Effectively Integrates Two Forms Of Molecular Data With Multiple Biologically Related Endpoints
Authors: Cao X. , Crews K.R. , Downing J. , Lamba J. , Pounds S.B. .
Source: Bmc Bioinformatics, 2016-10-06 00:00:00.0; 17(Suppl 13), p. 382.
PMID: 27766934
Related Citations

Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
Authors: Lamba J.K. , Pounds S. , Cao X. , Crews K.R. , Cogle C.R. , Bhise N. , Raimondi S.C. , Downing J.R. , Baker S.D. , Ribeiro R.C. , et al. .
Source: Leukemia & Lymphoma, 2016; 57(4), p. 909-20.
PMID: 26366682
Related Citations

Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis.
Authors: Ghodke-Puranik Y. , Puranik A.S. , Shintre P. , Joshi K. , Patwardhan B. , Lamba J. , Niewold T.B. , Chopra A. .
Source: Pharmacogenomics, 2015 Dec; 16(18), p. 2019-34.
PMID: 26616421
Related Citations

Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity.
Authors: Chauhan L. , Jenkins G.D. , Bhise N. , Feldberg T. , Mitra-Ghosh T. , Fridley B.L. , Lamba J.K. .
Source: Bmc Genomics, 2015-06-30 00:00:00.0; 16, p. 483.
EPub date: 2015-06-30 00:00:00.0.
PMID: 26121980
Related Citations

Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma.
Authors: Bachanova V. , Shanley R. , Malik F. , Chauhan L. , Lamba V. , Weisdorf D.J. , Burns L.J. , Lamba J.K. .
Source: Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation, 2015 May; 21(5), p. 944-8.
PMID: 25677220
Related Citations

MicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients.
Authors: Bhise N.S. , Chauhan L. , Shin M. , Cao X. , Pounds S. , Lamba V. , Lamba J.K. .
Source: Frontiers In Pharmacology, 2015; 6, p. 324.
PMID: 26858643
Related Citations

A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
Authors: Burke M.J. , Lamba J.K. , Pounds S. , Cao X. , Ghodke-Puranik Y. , Lindgren B.R. , Weigel B.J. , Verneris M.R. , Miller J.S. .
Source: American Journal Of Hematology, 2014 Sep; 89(9), p. 889-95.
PMID: 24891274
Related Citations

The most informative spacing test effectively discovers biologically relevant outliers or multiple modes in expression.
Authors: Pawlikowska I. , Wu G. , Edmonson M. , Liu Z. , Gruber T. , Zhang J. , Pounds S. .
Source: Bioinformatics (oxford, England), 2014-05-15 00:00:00.0; 30(10), p. 1400-8.
EPub date: 2014-05-15 00:00:00.0.
PMID: 24458951
Related Citations

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Authors: Khatri A. , Williams B.W. , Fisher J. , Brundage R.C. , Gurvich V.J. , Lis L.G. , Skubitz K.M. , Dudek A.Z. , Greeno E.W. , Kratzke R.A. , et al. .
Source: British Journal Of Cancer, 2014-01-21 00:00:00.0; 110(2), p. 304-12.
EPub date: 2014-01-21 00:00:00.0.
PMID: 24300978
Related Citations

Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Authors: Lamba J.K. , Fridley B.L. , Ghosh T.M. , Yu Q. , Mehta G. , Gupta P. .
Source: Pharmacogenomics, 2014; 15(12), p. 1565-74.
PMID: 25340731
Related Citations

RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
Authors: Cao X. , Mitra A.K. , Pounds S. , Crews K.R. , Gandhi V. , Plunkett W. , Dolan M.E. , Hartford C. , Raimondi S. , Campana D. , et al. .
Source: Pharmacogenomics, 2013 Sep; 14(12), p. 1449-66.
PMID: 24024897
Related Citations

Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
Authors: Gamazon E.R. , Lamba J.K. , Pounds S. , Stark A.L. , Wheeler H.E. , Cao X. , Im H.K. , Mitra A.K. , Rubnitz J.E. , Ribeiro R.C. , et al. .
Source: Blood, 2013-05-23 00:00:00.0; 121(21), p. 4366-76.
EPub date: 2013-05-23 00:00:00.0.
PMID: 23538338
Related Citations

Valproic acid pathway: pharmacokinetics and pharmacodynamics.
Authors: Ghodke-Puranik Y. , Thorn C.F. , Lamba J.K. , Leeder J.S. , Song W. , Birnbaum A.K. , Altman R.B. , Klein T.E. .
Source: Pharmacogenetics And Genomics, 2013 Apr; 23(4), p. 236-41.
PMID: 23407051
Related Citations

Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
Authors: Mortland L. , Alonzo T.A. , Walter R.B. , Gerbing R.B. , Mitra A.K. , Pollard J.A. , Loken M.R. , Hirsch B. , Raimondi S. , Franklin J. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2013-03-15 00:00:00.0; 19(6), p. 1620-7.
EPub date: 2013-03-15 00:00:00.0.
PMID: 23444229
Related Citations

PharmGKB summary: zidovudine pathway.
Authors: Ghodke Y. , Anderson P.L. , Sangkuhl K. , Lamba J. , Altman R.B. , Klein T.E. .
Source: Pharmacogenetics And Genomics, 2012 Dec; 22(12), p. 891-4.
PMID: 22960662
Related Citations

Assessment of healthcare students' views on pharmacogenomics at the University of Minnesota.
Authors: Moen M. , Lamba J. .
Source: Pharmacogenomics, 2012 Oct; 13(13), p. 1537-45.
PMID: 23057552
Related Citations

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Authors: Mitra A.K. , Kirstein M.N. , Khatri A. , Skubitz K.M. , Dudek A.Z. , Greeno E.W. , Kratzke R.A. , Lamba J.K. .
Source: Pharmacogenomics, 2012 Jul; 13(9), p. 1009-21.
PMID: 22838949
Related Citations

Pharmacogenomics of cytarabine in childhood leukemia.
Authors: Lamba J.K. .
Source: Pharmacogenomics, 2011 Dec; 12(12), p. 1629-32.
PMID: 22118048
Related Citations

Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
Authors: Mitra A.K. , Crews K.R. , Pounds S. , Cao X. , Feldberg T. , Ghodke Y. , Gandhi V. , Plunkett W. , Dolan M.E. , Hartford C. , et al. .
Source: The Journal Of Pharmacology And Experimental Therapeutics, 2011 Oct; 339(1), p. 9-23.
PMID: 21712425
Related Citations

Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study.
Authors: Mitra A.K. , Crews K. , Pounds S. , Cao X. , Downing J.R. , Raimondi S. , Campana D. , Ribeiro R.C. , Rubnitz J.E. , Lamba J.K. .
Source: Leukemia, 2011 Aug; 25(8), p. 1354-6.
PMID: 21483441
Related Citations

The emerging role of electronic medical records in pharmacogenomics.
Authors: Wilke R.A. , Xu H. , Denny J.C. , Roden D.M. , Krauss R.M. , McCarty C.A. , Davis R.L. , Skaar T. , Lamba J. , Savova G. .
Source: Clinical Pharmacology And Therapeutics, 2011 Mar; 89(3), p. 379-86.
PMID: 21248726
Related Citations

Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
Authors: Lamba J.K. , Crews K.R. , Pounds S.B. , Cao X. , Gandhi V. , Plunkett W. , Razzouk B.I. , Lamba V. , Baker S.D. , Raimondi S.C. , et al. .
Source: Pharmacogenomics, 2011 Mar; 12(3), p. 327-39.
PMID: 21449673
Related Citations

Genetic factors influencing cytarabine therapy.
Authors: Lamba J.K. .
Source: Pharmacogenomics, 2009 Oct; 10(10), p. 1657-74.
PMID: 19842938
Related Citations

PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables.
Authors: Pounds S. , Cheng C. , Cao X. , Crews K.R. , Plunkett W. , Gandhi V. , Rubnitz J. , Ribeiro R.C. , Downing J.R. , Lamba J. .
Source: Bioinformatics (oxford, England), 2009-08-15 00:00:00.0; 25(16), p. 2013-9.
EPub date: 2009-08-15 00:00:00.0.
PMID: 19528086
Related Citations